The Group has obtained Series A investment of approximately RMB20 million

(Summary description)

The Group has obtained Series A investment of approximately RMB20 million

(Summary description)

Information
The Group has obtained Series A investment of approximately RMB20 million

Scan the QR code to read on your phone

Previous: The GT0918 (Proxalutamide tablets) project has obtained clinical trials permission for prostate cancer indications in China and the United States, and phase I clinical trials have been launched in China
Next: The IND application of the Group's first project, GT0918 (Proxalutamide tablets), has been submitted for prostate cancer indications
Previous: The GT0918 (Proxalutamide tablets) project has obtained clinical trials permission for prostate cancer indications in China and the United States, and phase I clinical trials have been launched in China
Next: The IND application of the Group's first project, GT0918 (Proxalutamide tablets), has been submitted for prostate cancer indications